Our findings suggest that targeting MUC5B in the terminal airways of patients with preclinical stages of interstitial lung disease represents a rational strategy to prevent the progression of preclinical pulmonary fibrosis. This evidence concerns the gene MUC5B and pulmonary fibrosis.